Business Wire

ADVA announces preliminary results for fiscal year 2022

21.2.2023 07:00:00 EET | Business Wire | Press release

Share

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported preliminary, unaudited financial results for Q4 2022 and full year 2022 ended on December 31, 2022. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). The final audited annual financial statements, consolidated financial statements and annual report 2022 will be published on March 09, 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005296/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Christoph Glingener, CEO, ADVA (Photo: Business Wire)

Q4 2022 financial summary1

(in thousands of EUR)

Q4

Q4

Change

Q3

Change

 

2022

2021

 

2022

 

 

Revenues

195,699

157,713

24.1%

179,597

9.0%

Pro forma gross profit

71,434

56,072

27.4%

60,857

17.4%

in % of revenues

36.5%

35.6%

0.9pp

33.9%

2.6pp

Pro forma EBIT

24,407

14,362

69.9%

11,732

108.0%

in % of revenues

12.5%

9.1%

3.4pp

6.5%

6.0pp

Operating income2

14,803

11,190

32.3%

-7,322

n/a

Net income

3,781

17,511

-78.4%

881

329 .2%

 

(in thousands of EUR)

Dec. 31

2022

Dec. 31

2021

Change

Sep. 30

2022

Change

Cash and cash equivalents

58,447

108,987

-46.4%

61,381

-4.8%

Net cash (+) / Net debt (-)

-19,185

36,166

n/a

-17,434

10.0%

1 Potential difference due to rounding

2 Q4 2022 including EUR 3.3 million, Q4 2021 including EUR 1.6 million and Q3 2022 including EUR 17.1 million extraordinary expenses

Q4 2022 IFRS financial results

Revenues in Q4 2022 reached EUR 195.7 million, up by 9.0% from EUR 179.6 million in Q3 2022, also up by 24.1% compared to EUR 157.7 million in Q4 2021. This was due, in particular, to very high demand from telecommunications service providers.

Pro forma gross profit in Q4 2022 increased by 17.4%, reaching EUR 71.4 million (36.5% of revenues) compared to EUR 60.9 million (33.9% of revenues) in Q3 2022 and increased by 27.4% compared to EUR 56.1 million (35.6% of revenues) reported in Q4 2021. The margin increase was due to a reduction in freight costs and expedited fees associated with the semiconductor crisis.

Pro forma EBIT for Q4 2022 was EUR 24.4 million (12.5% of revenues) and increased by 108.0% compared to EUR 11.7 million (6.5% of revenues) reported in Q3 2022. Compared to Q4 2021, pro forma EBIT improved by 69.9% from EUR 14.4 million (9.1% of revenues).

Operating income for Q4 2022 of EUR 14.8 million increased from an operating loss of EUR 7.3 million reported for Q3 2022 and increased by 32.3% from EUR 11.2 million in Q4 2021. The year-ago quarter was impacted by higher purchasing costs, and the previous quarter was impacted by both higher purchasing costs and expenses related to the business combination with Adtran.

Net income reached EUR 3.8 million in Q4 2022 and increased by 329.2% from EUR 0.9 million in Q3 2022 but decreased by 78.4% from EUR 17.5 million in Q4 2021.

The company’s cash and cash equivalents totaled EUR 58.4 million, compared to EUR 61.4 million at the end of Q3 2022 or EUR 109.0 million at the end of Q4 2021. Net debt at the end of Q4 2022 stood at EUR 19.2 million compared to EUR 17.4 million at the end of Q3 2022 or a net cash position of EUR 36.2 million at the end of Q4 2021. The comparatively high level of net debt is attributable to higher debt-financed inventories.

Full year 2022 financial summary1

(in thousands of EUR)

2022

2021

Change

Revenues

712,114

603,317

18.0%

Pro forma gross profit

240,032

220,844

8.7%

in % of revenues

33.7%

36.6%

-2.9pp

Pro forma EBIT2

50,386

54,649

-7.8%

in % of revenues

7 .1%

9.1 %

-2.0pp

Operating income3

18,112

45,295

-60.0%

Net income

18,132

59,218

-69.4%

 

(in thousands of EUR)

Dec. 31 2022

Dec. 31 2021

Change

Cash and cash equivalents

58,447

108,987

-46.4%

Net cash (+) / Net debt (-)

-19,185

36,166

n/a

1 Potential differences due to rounding

2 Prior: Pro forma operating income

3 2022 including EUR 21.3 million and 2021 including EUR 3.7 million extraordinary expenses

Full year 2022 IFRS financial results

For the full year 2022, revenues increased by 18.0%, from EUR 603.3 million in 2021 to EUR 712.1 million. Revenues were within the guidance corridor of between EUR 680 million and 730 million. Despite the continuing challenges posed by global supply bottlenecks and material shortages in the semiconductor industry, ADVA substantially increased its revenues. Demand notably increased in the telecommunications service provider segment.

Pro forma gross profit increased 8.7% from EUR 220.8 million (36.6%) in 2021 to EUR 240.0 million (33.7%) in 2022. Full year gross margins were impacted by increased freight costs and expedited fees associated with the semiconductor crisis.

Pro forma EBIT for 2022 decreased by 7.8%, from 54.6 million or 9.1% of revenues in 2021 to EUR 50.4 million or 7.1% of revenues. Pro forma EBIT was within the guidance corridor of between 5.0% and 9.0%.

Operating income decreased by 60.0%, from EUR 45.3 million in 2021 to EUR 18.1 million in 2022. The results for 2022 were impacted by higher costs resulting from the supply chain crisis and expenses related to the business combination with Adtran.

Consequently, net income decreased from EUR 59.2 million in 2021 by 69.4% to EUR 18.1 million in 2022.

Basic earnings per share in 2022 amounted to EUR 0.35 compared to EUR 1.17 in 2021. Diluted earnings per share in 2022 also amounted to EUR 0.35 compared to diluted earnings per share of EUR 1.15 in 2021.

Management commentary

“We’re proud to report a highly successful fiscal year, where we achieved the highest revenues in our company’s history. Despite ongoing challenges caused by the semiconductor crisis, bottlenecks in the supply chains, inflation and fears of recession, we were able to stay on course, comprehensively serving and supporting our customers with innovative communications technology, software and services,” said Christoph Glingener, CEO of ADVA. “Looking forward, we are optimistic about future growth prospects. We have a strong pipeline of new products and services and are well-positioned to benefit from the major trends in our industry. Our capabilities in software and services are strengthening, delivering increasing value to our customers and partners. Together with Adtran, we will continue to focus on cost management and operational efficiency while investing in key areas to enter new growth markets.”

“Today, we report financial results of a strong 2022 with revenue growth of 18% year-over-year. Considering the various macroeconomic challenges and ongoing constraints in global supply chains, we’re very pleased with our profitability, which came in as expected,” commented Uli Dopfer, CFO of ADVA. “We’re optimistic that global supply chains will ease during this year and that cash generation will improve. We also expect to benefit from our business combination with Adtran and see first revenue synergies in 2023. We remain committed to increasing software and service revenues, which will drive continued margins improvement.”

The company will publish its financial results for Q1 2023 on May 09, 2023.

Conference call details

ADVA will hold a conference call for analysts and investors today, February 21, 2023, to discuss the preliminary Q4 2022 and full year 2022 results. The company’s CEO, Christoph Glingener, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CET (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website: https://www.adva.com/en/about-us/investors/financial-results/conference-calls

A replay of the call will be available here: https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete annual report 2022 (January – December) will be published on March 09, 2023.

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses related to M&A and restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Steven Williams
t +49 89 890 66 59 18
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye